Company profile
Item 9 Labs Corp.
OTC: INLB · Healthcare · Drug Manufacturers - Specialty & Generic
#536 of 1,418 Healthcare companies by revenue40th-percentile growth
EA Score
——FH —DQ 36GM —SS 49
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, listing tenure · ↓ growth stability, filing timeliness
Methodology →Revenue TTM
$19.7M
Rev growth YoY (TTM)
-17.4%
Net income (FY)
-$31.2M
Employees
97
as of 2026-08-28
Market cap
$70.2k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$21.8M$21.8M2022
Net income-$31.2M-$31.2M2022
Operating income-$23.1M-$23.1M2022
Total assets$110.8M$110.8M2022
Liabilities$48.8M$48.8M2022
Equity$62.0M$62.0M2022
Revenue trend
FY2013 – FY2022 · USD
FY13
FY14
FY15
FY19
FY19
FY20
FY21
FY22
Revenue by segment
Filed disclosures · FY2022
By product
Corporate and Other50%
Cultivation49%
Franchising1%
Corporate0%
By geography
Not disclosed.
The read
What is Item 9 Labs Corp.’s revenue?
Item 9 Labs Corp. booked $21.8M in FY2022 revenue, contracting 0.8% year over year — about the middle of the pack among Healthcare companies we track, at a -143.3% net margin.
Peers · Healthcare
NextCure, Inc.38DDarioHealth Corp.49DAyurcann Holdings Corp.57CSQZ Biotechnologies Company——Alector, Inc.40DMaxCyte, Inc.48DNeighbors
Maricopa →Key facts
CEOJeffrey I. Rassas
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersPhoenix, AZ
ExchangeOTC: INLB
Employees97
IPO date2012-01-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.